– USA, NC – Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced the appointment of Jeff Hartness to its Board of Directors.
“Jeff’s diverse background crosses all channels and segments of the pharmaceutical business making him a perfect fit to continue to strengthen our team’s commercial expertise. We look forward to working with Jeff and the rest of the Board as we continue to enhance our commercial planning for UTULY,” said Co-Founder, Michelle Lobel.
“Jeff brings a deep knowledge of the ever-changing and complex payer, market, and government landscape that are critical to ensure patients and physicians have access to needed innovative products. We are thrilled to welcome him to our esteemed Board,” said CEO, Dr. David Dworaczyk.
About Jeff Hartness
Jeff Hartness brings more than 25 years of leadership and success in creating and executing go-to-market strategies in the healthcare space to Bryn’s Board. He has launched dozens of products in disease states including small molecules, specialty/biologics, devices, OTCs, and generics. He is currently a member of Bausch Health Company’s Global Executive Committee as SVP and Head of Market Access, Commercial Operations, Policy, and Government Affairs. In this role, he focuses on the commercialization strategy of pricing, contracting, and the creation of patient access to Bausch Health products, as well as the distribution of those products throughout the healthcare system. Before joining Bausch Health, Mr. Hartness spent 15 years at Sanofi in various leadership roles, including Product Launch Execution and as the Head of Pharmacy Benefit Managers, Employers, and Specialty business. Mr. Hartness currently serves on the Board of Directors for Corganics, a privately held clinical cannabinoid life sciences company based in Dallas, Texas.
About Bryn Pharma
Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction.
For more information: https://www.brynpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.